Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irinotecan - Yakult Honsha

Drug Profile

Irinotecan - Yakult Honsha

Alternative Names: Campotesin; Campto; Camptosar; CPT-11; DQ 2805; IHL-305; Irinotecan hydrochloride; Irinotecan liposome injection; Irinotecan semi-solid matrix; Irinotecan SSM; Irkan; Irnocam; SN 38B11; Topotecin; U 101440E

Latest Information Update: 19 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yakult Honsha
  • Developer Daiichi Sankyo Company; Pfizer; Sanofi; Yakult Honsha
  • Class Alkaloids; Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Cervical cancer; Colorectal cancer; Gastrointestinal cancer; Leukaemia; Lung cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Skin cancer; Small cell lung cancer; Solid tumours; Uterine cancer
  • Phase II Gastric cancer
  • Discontinued Mesothelioma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Liposomal)
  • 20 Dec 2013 Launched for Pancreatic cancer (unresectable) in Japan (IV)
  • 20 Dec 2013 Launched for Solid tumours (in children) in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top